Furthermore, in MCL, a robust synergy was observed between the HSP90 inhibitor, LAM-003 and venetoclax in FLT3-ITD AML cells, a particularly aggressive and resistant cell type [148]. The gene discussed is FLT3; the disease is acute myeloid leukemia.